While Compass Therapeutics Inc has overperformed by 1.30%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, CMPX rose by 149.60%, with highs and lows ranging from $3.63 to $0.76, whereas the simple moving average jumped by 101.36% in the last 200 days.
On December 23, 2024, D. Boral Capital started tracking Compass Therapeutics Inc (NASDAQ: CMPX) recommending Buy. A report published by Leerink Partners on November 15, 2024, Downgraded its rating to ‘Market Perform’ for CMPX. Ladenburg Thalmann also Upgraded CMPX shares as ‘Buy’, setting a target price of $5 on the company’s shares in a report dated September 16, 2024. Jefferies Initiated an Buy rating on January 31, 2023, and assigned a price target of $8. Stifel initiated its ‘Buy’ rating for CMPX, as published in its report on January 27, 2023. H.C. Wainwright’s report from May 23, 2022 suggests a price prediction of $12 for CMPX shares, giving the stock a ‘Buy’ rating. Ladenburg Thalmann also rated the stock as ‘Buy’.
Analysis of Compass Therapeutics Inc (CMPX)
In order to gain a clear picture of Compass Therapeutics Inc’s future performance, a variety of well-rounded analysis and research techniques can be applied, with equity being the most critical. The goal here is to ensure that your current return on equity of -32.01% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 31.84, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
An average volume of 1.25M can be a very valuable indicator of volatility for CMPX stock. On a monthly basis, the volatility of the stock is set at 16.33%, whereas on a weekly basis, it is put at 9.31%, with a loss of -3.11% over the past seven days. Furthermore, long-term investors anticipate a median target price of $11.00, showing growth from the present price of $3.12, which can serve as yet another indication of whether CMPX is worth investing in or should be passed over.
How Do You Analyze Compass Therapeutics Inc Shares?
In addition to the fundamentals, you should also consider how many employees own shares in the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 39.51%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 43.54% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
CMPX shares are owned by institutional investors to the tune of 43.54% at present.
